読み込み中
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
前日終値
$2.77
+$0.015 · +0.54%
市場前
$2.89
+$0.12 · +4.33%
10月13日 7:00 ET
日中の時刻はETです。市場データは遅延する場合があります。
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
日中レンジ
現在 $2.77
52週レンジ
現在 $2.77
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
35
割高
センチメント
43
まちまち
リスク
70
高リスク
モメンタム
33
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
日中レンジ
現在 $2.77
52週レンジ
現在 $2.77
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 36.2万 USD | — | 34.1万 USD | — | — |
| 粗利益 | −36.2万 USD | — | −34.1万 USD | — | — |
| 研究開発 | 4263.3万 USD | 3170.4万 USD | 2478.5万 USD | 1680.8万 USD | 2108.8万 USD |
| 販売・一般管理 | 2191.6万 USD | 1745万 USD | 1862.4万 USD | 2073.7万 USD | 2640.1万 USD |
| 営業費用 | 6418.7万 USD | 4915.4万 USD | 4327.2万 USD | 6706.2万 USD | 4748.9万 USD |
| 受取利息 | 633.1万 USD | 413.5万 USD | 272.7万 USD | 111万 USD | 23.7万 USD |
| 支払利息 | — | — | — | 113.7万 USD | 173.7万 USD |
| 減価償却費と償却費 | 36.2万 USD | 33.2万 USD | 34.1万 USD | 24.8万 USD | 11.7万 USD |
| 営業利益 | −6454.9万 USD | −4915.4万 USD | −4361.3万 USD | −6706.2万 USD | −4748.9万 USD |
| 純利益 | −5743.9万 USD | −4459.6万 USD | −4042万 USD | −6595.2万 USD | −4725.2万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$12.00
上昇余地（333.21%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2020年1月10日 | 1:40 | — | — |
発効済み 2020年1月10日
1:40
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI639.94万0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM380.96万0.00%787.4億 USD0.19%$277.9-0.37%
Vanguard Extended Market ETFVXF226.57万0.00%954億 USD0.05%$233.52-0.63%
Vanguard Russell 2000 ETFVTWO115.78万0.01%180億 USD0.06%$112.27-0.35%
Dimensional - US Small Cap ETFDFAS91.98万0.00%338.04億 USD0.31%$78.17-0.23%
Vanguard U.S. Momentum Factor ETFVFMO54.24万0.03%19億 USD0.13%$227.71-1.04%
iShares Micro-Cap ETFIWC46.04万0.03%13.17億 USD0.60%$181.66-0.73%
U.S. Micro Cap Portfolio ETFDFMC41.16万0.01%75.44億 USD0.43%$57.70-0.20%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASVanguard U.S. Momentum Factor ETFVFMOiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
